Clinical Trials Browser

Carcinoma in Situ × Nivolumab × Genitourinary × Clear all

NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Phase 1 Terminated

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell